AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$RMD

ResMed: Fiscal Q1 Earnings Snapshot

ResMed Inc. (RMD) reported fiscal Q1 net income of $418.4M, or $2.92 per share, beating estimates. Revenue was $1.41B, also surpassing forecasts. The company expects full-year earnings of $12-$12.25 per share, according to Zacks Investment Research.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ResMed: Fiscal Q1 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RMDBullishMed
01

Why it matters

The key tradable inputs are the EPS and revenue beats versus Zacks consensus and the stated full-year earnings range, which together can shift expectations for the remainder of the fiscal year.

02

Market read

Company-specific earnings beat and explicit full-year guidance create a clear near-term catalyst for RMD positioning.

03

What to watch

The article does not break out segment performance, margins, or cash flow, which can drive post-earnings divergence even after EPS and revenue beats.

Relevance 9/10Novelty 8/10Timing: reported fiscal Q1 results on Thursday

Background

ResMed is a medical products company focused on respiratory disorders; this is its fiscal first-quarter earnings snapshot.

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

ResMed reported fiscal Q1 net income of $418.4M and EPS $2.92, beating Zacks estimates, and revenue $1.41B also topped forecasts.

Expected impact

Likely upward bias as the market digests the EPS and revenue beat and compares the $12 to $12.25 full-year range to Street expectations.

Evidence & confidence

The article provides a first-quarter EPS and revenue beat versus analyst estimates and includes explicit full-year guidance, which are direct drivers of near-term repricing.

Market effects

Sector

Positive read-through for respiratory medical device peers if investors generalize demand strength from the beat.

Regional

Limited, primarily company-specific unless broader healthcare earnings season shows similar outperformance.

Global

Low, as the disclosure is company-specific and not tied to a global macro policy or supply shock.

Counterpoint

What could challenge this read

A beat may already be partially priced; traders may focus on whether the $12 to $12.25 full-year range implies deceleration versus prior guidance.

Key entities

  • company
    ResMed Inc.

    Reported fiscal Q1 net income, EPS, revenue, and provided full-year earnings guidance.

  • source
    Zacks Investment Research

    Provided the analyst consensus estimates referenced in the article.

Read at source← All news

StoryResMed posts Q1 FY27 beat with $1.4 B revenue, $2.91 EPS and $1 B returned to shareholders

Also covered by

4 outlets

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com